WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Andrew Abbott handcuffs Padres as Reds rebound from disastrous road trip to win 2
VOX POPULI: The special charm of Gaudi’s unfinished work: Sagrada Familia
South China Sea news: Chinese media slams Australian warship at centre of sonar incident
Will Stonehenge lose its Unesco World Heritage status?
Closing prices for crude oil, gold and other commodities
Multiple people shot outside Ramadan celebration in Philadelphia
VOX POPULI: What jobs do children want to take in the future?
Petrobras paid BRL 240.2 bi in taxes and royalties in 2023
Bell's RBI single in 10th lifts Marlins to 3
Third person arrested over Palmerston North man's murder
Retired judge finds no reliable evidence against Quebec cardinal; purported victim declines to talk
Splore festival to take 2025 off after posting loss